It induces upregulation of the mammalian target of rapamycin (mTOR) pathway, shifting activity away from subcortical and limbic regions and toward the medial and lateral prefrontal cortex [15], and has the potential to reverse the mTOR signaling pathway impairment that is seen in major depressive disorder (MDD) [22]. The gene discussed is MTOR; the disease is major depressive disorder.